The U.S. Food and Drug Administration approved Sanofi and Merck & Co. Inc.'s Vaxelis as a vaccine to prevent certain diseases in children from 6 weeks through 4 years of age.
Vaxelis, which was developed as part of a joint partnership between Sanofi and Merck, received the FDA's approval to prevent diphtheria, tetanus, whooping cough, polio, hepatitis B and invasive disease due to Haemophilus influenzae type b.
Sanofi and Merck said in a Dec. 26 news release that they are planning to maximize production of Vaxelis to allow for a "sustainable supply to meet anticipated U.S. demand."
Commercial supply of Vaxelis will not be available in the U.S. before 2020.
The European Medicines Agency has already approved Vaxelis as a primary and booster vaccination in infants and toddlers from the age of 6 weeks for the same diseases.